Drug Reactions Affecting the Nail Unit: Diagnosis and Management

Dermatologic Clinics

Volumn 25, Issue 2, 2007, Pages 215-221

  Piraccini, Bianca Maria ^a   Iorizzo, Matilde ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CARBAMAZEPINE; CEFALORIDINE; CLOXACILLIN; CORTICOSTEROID; CYCLOSPORIN A; DAPSONE; DOXORUBICIN; ETRETIN; ETRETINATE; FLUCONAZOLE; FLUORINE; HEPARIN; HYDANTOIN; ISOTRETINOIN; ITRACONAZOLE; LEVODOPA; LITHIUM; METHOTREXATE; ORAL CONTRACEPTIVE AGENT; PENICILLAMINE; PHENOLPHTHALEIN; PSORALEN; SULFONAMIDE; TETRACYCLINE; TRIMETHADIONE; VALPROIC ACID; WARFARIN; ZIDOVUDINE;

BEAU LINE; DIAGNOSTIC PROCEDURE; DISEASE MANAGEMENT; FINGER MALFORMATION; HUMAN; ISCHEMIA; LEUKONYCHIA; MELANONYCHIA; NAIL ATROPHY; NAIL DISEASE; NAIL HYPOPLASIA; ONYCHOLYSIS; ONYCHOMADESIS; ONYCHORRHEXIS; PARONYCHIA; PATHOGENESIS; PRIORITY JOURNAL; PYOGENIC GRANULOMA; REVIEW; SUBUNGUAL HEMORRHAGE; TERATOGENESIS;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; HUMANS; NAIL DISEASES; NAILS; RETINOIDS;

EID: 34047275792     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2007.01.006     Document Type: Review

References (48)

1. Tosti A., Baran R., and Dawber R.P.R. The nail in systemic diseases and drug-induced changes. In: Baran R., Dawber R.P.R., de Berker D.A.R., et al. (Eds). Baran and Dawber's diseases of the nails and their management. 2nd edition (2001), Blackwell Science, Oxford 223-229
2. Daniel III C.R., and Scher R.K. Nail changes secondary to systemic drugs or ingestans. J Am Acad Dermatol 10 (1984) 250-258
3. Piraccini B.M., and Tosti A. Drug-induced nail disorders. Incidence, management and prognosis. Drug Saf 21 (1999) 187-201
4. Piraccini B.M., Iorizzo M., and Tosti A. Drug-induced nail abnormalities. Am J Clin Dermatol 4 (2003) 31-37
5. Piraccini B.M., Iorizzo M., Antonucci A., et al. Drug-induced nail abnormalities. Expert Opin Drug Saf 3 (2004) 57-65
6. Pettifor J.M., and Benson R. Congenital malformation with the administration of oral anticoagulant during pregnancy. J Pediatr 86 (1975) 459-462
7. Holmes L.B., Harvey E.A., Brown K.S., et al. Anti-convulsant teratogenesis: I. A study design for newborn infants. Teratology 49 (1994) 202-207
8. Minisini A.M., Tosti A., Sobrero A.F., et al. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol 14 (2003) 333-337
9. Baran R. Retinoids and the nail. J Dermatolog Treat 1 (1990) 151-154
10. Eastwood J.B., Curtis J.R., Smith E.K., et al. Shedding of nails apparently induced by the administration of large amounts of cephaloridine and cloxacillin in two anephric patients. Br J Dermatol 81 (1969) 750-752
11. Chen H.H., and Liao Y.H. Beau's lines associated with itraconazole. Acta Derm Venereol 82 (2002) 398
12. de Doncker P., and Pierard G.E. Acquired nail beading in patients receiving itraconazole-an indicator of faster nail growth? A study using optical profilometry. Clin Exp Dermatol 19 (1994) 404-406
13. Miller E. Levodopa and nail growth. N Engl J Med 288 (1973) 916
14. Chapman S., and Cohen P.R. Transverse leukonychia in patients receiving cancer chemotherapy. South Med J 90 (1997) 395-398
15. Shelley W.B., and Humprey G.B. Transverse leukonychia (Mees' lines) due to daunorubicin chemotherapy. Pediatr Dermatol 14 (1997) 144-145
16. Baran R., and Juhlin L. Photoonycholysis. Photodermatol Photoimmunol Photomed 18 (2002) 202-207
17. Hussain S., Anderson D.N., Salvatti M.E., et al. Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer 88 (2000) 2367-2371
18. Vanhooteghem O., Richert B., Vindevoghel A., et al. Subungual abscess: a new ungual side effect related to docetaxel therapy. Br J Dermatol 143 (2000) 462-464
19. Wasner G., Hilpert F., Baron R., et al. Nail changes secondary to docetaxel. Lancet 357 (2001) 910
20. Chang J.C. Acute bullous dermatosis and onycholysis due to high-dose methotrexate and leucovorin calcium. Arch Dermatol 123 (1987) 990-992
21. Gaylis N. Infliximab in the treatment of an HIV positive patient with Reiter's syndrome. J Rheumatol 30 (2003) 407-411
22. Wantzin G.L., and Thomsen K. Acute paronychia after high-dose methotrexate therapy. Arch Dermatol 119 (1983) 623-624
23. Zerboni R., Angius A.G., Cusini M., et al. Lamivudine-induced paronychia. Lancet 351 (1998) 1256
24. Tosti A., Piraccini B.M., D'Antuono A., et al. Paronychia associated with antiretroviral therapy. Br J Dermatol 140 (1999) 1165-1168
25. Blumental G. Paronychia and pyogenic granuloma-like lesions with isotretinoin. J Am Acad Dermatol 10 (1984) 677-678
26. Bouscarat F., Bouchard C., and Bouhour D. Paronychia and pyogenic granuloma of the great toes in patients with indinavir. N Engl J Med 338 (1998) 1776-1777
27. Calista D., and Boschini A. Cutaneous side effects induced by indinavir. Eur J Dermatol 10 (2000) 292-296
28. Busam K.J., Capodieci P., Motzer R., et al. Cutaneous side effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144 (2001) 1169-1176
29. Boucher K.W., Davidson K., Mirakhur B., et al. Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J Am Acad Dermatol 47 (2002) 632-633
30. Nakano J., and Nakamura M. Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Dermatol 30 (2003) 261-262
31. Robert C., Soria J.C., Spatz A., et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6 (2005) 491-500
32. Maloney D.M., Schmidt J.D., and Duvic M. Alitretinoin gel to treat pyogenic granuloma. J Am Acad Dermatol 47 (2002) 969-970
33. Stringer M.D., and Bentley P.G. Peripheral gangrene associated with β-blockade. Br J Surg 73 (1986) 1008
34. Snauwaert J., and Degreef H. Bleomycin-induced Raynaud's phenomenon and acral sclerosis. Dermatologica 169 (1984) 172-174
35. Varotti C., Ghetti E., Piraccini B.M., et al. Subungual hematoma in a patient treated with an oral anticoagulant (warfarin sodium). Eur J Dermatol 7 (1997) 395-396
36. Ghetti E., Piraccini B.M., and Tosti A. Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel). J Eur Acad Dermatol Venereol 17 (2003) 459-460
37. Lorenzi S., D'Antuono A., Iorizzo M., et al. Skin rash and splinter haemorrhages from ganciclovir. J Dermatolog Treat 14 (2003) 177-178
38. Wolf R., Tur E., and Brenner S. Corticosteroid-induced "disappearing digit". J Am Acad Dermatol 23 (1990) 755-756
39. Baran R., and Kechijian P. Longitudinal melanonychia: diagnosis and management. J Am Acad Dermatol 21 (1989) 1165-1175
40. Nixon D.W. Alterations in nail pigment with cancer chemotherapy. Arch Intern Med 136 (1976) 1117-1118
41. Aste N., Fumo G., Contu F., et al. Nail pigmentation caused by hydroxyurea: report of 9 cases. J Am Acad Dermatol 47 (2002) 146-147
42. Ledbetter L.S., and Hsu S. Melanonychia associated with PUVA therapy. J Am Acad Dermatol 48 (2003) 31-32
43. Shelley W.B., Rawnsley H.M., and Pillsbury D.M. Postirradiation melanonychia. Arch Dermatol 90 (1964) 174-176
44. Hendricks A.A. Yellow lunulae with fluorescence after tetracycline therapy. Arch Dermatol 116 (1980) 438-440
45. Fam A.G., and Paton T.W. Nail pigmentation after parenteral gold therapy for rheumatoid arthritis: "gold nails". Arthritis Rheum 27 (1984) 119-120
46. Tosti A, Piraccini BM, Guerra L. Reversible melanonychia due to clofazimine. 18th World Congress of Dermatology, New York, (1992): 183A.
47. Kimyai-Asadi A., and Jih M.H. Minocycline induced nail-bed pigmentation. J Drugs Dermatol 1 (2002) 197-198
48. Tuffanelli D., Abraham R.K., and Dubois E.I. Pigmentation from antimalarial therapy. Arch Dermatol 88 (1963) 113-120